Wechselwirkungen von Sumatriptan und Naproxen

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Amfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (Fachinformation zu Amfetamin und Dexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Apixaban, Boxed Warning (umrahmter Warnhinweis))

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Belladonna und Opium, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (Fachinformation zu Buspiron, Warnhinweise)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Arzneimittelwechselwirkungen)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Butorphanol, Vorsichtsmaßnahmen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (Fachinformation zu Cidofovir, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Codein, Arzneimittelwechselwirkungen)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (Fachinformation zu Cyclobenzaprin, Warnhinweise und Vorsichtsmaßnahmen)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Dabigatran, Boxed Warning (umrahmter Warnhinweis))

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (Fachinformation zu Dexamfetamin, Warnhinweise)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Edoxaban, Boxed Warning (umrahmter Warnhinweis))

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (Fachinformation zu Enoxaparin, Boxed Warning (umrahmter Warnhinweis))

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (Fachinformation zu Fondaparinux, Boxed Warning (umrahmter Warnhinweis))

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Granisetron, Warnhinweise und Vorsichtsmaßnahmen)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Paracetamol, Vorsichtsmaßnahmen)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Levorphanol, Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Lisdexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Fachinformation zu Lithium, Warnhinweise und Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

Methotrexate Clinical Impact: Concomitant administration of some NSAIDs with high-dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (Fachinformation zu Mirtazapin, Warnhinweise und Vorsichtsmaßnahmen)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (Fachinformation zu Misoprostol, Boxed Warning (umrahmter Warnhinweis))

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (Fachinformation zu Montelukast, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Morphin, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Ondansetron, Warnhinweise und Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Palonosetron, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Paracetamol und Codein, Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Pentazocin und Naloxon, Vorsichtsmaßnahmen)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Pethidin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (Fachinformation zu Pralatrexat, Arzneimittelwechselwirkungen)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (Fachinformation zu Prasugrel, Boxed Warning (umrahmter Warnhinweis))

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Promethazin und Codein, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Remifentanil, Warnhinweise und Vorsichtsmaßnahmen)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Rivaroxaban, Boxed Warning (umrahmter Warnhinweis))

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Tapentadol, Warnhinweise und Vorsichtsmaßnahmen)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (Fachinformation zu Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (Fachinformation zu Sumatriptan und Naproxen, Gegenanzeigen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (Fachinformation zu Adefovir, Warnhinweise und Vorsichtsmaßnahmen)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Fachinformation zu Afatinib, Warnhinweise und Vorsichtsmaßnahmen)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Alendronsäure, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Anagrelid, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (Fachinformation zu Cefotaxim, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Cyclosporine Clinical Impact: Concomitant use of NSAIDs and cyclosporine may increase cyclosporine’s nephrotoxicity. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (Fachinformation zu Dapagliflozin, Arzneimittelwechselwirkungen)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Fachinformation zu Deferasirox, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Digoxin: Concomitant use with sumatriptan and naproxen sodium tablets can increase serum concentration and prolong half-life of digoxin. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (Fachinformation zu Droxidopa, Arzneimittelwechselwirkungen)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Fachinformation zu Febuxostat, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Naproxen Coadministration (N=18) of naproxen sodium capsules (250 mg) with NEURONTIN (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%. (Fachinformation zu Gabapentin, Arzneimittelwechselwirkungen)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Fachinformation zu Galantamin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Ibandronsäure, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (Fachinformation zu Kaliumcitrat, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (Fachinformation zu Levofloxacin, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Memantin und Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (Fachinformation zu Mifepriston, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (Fachinformation zu Moxifloxacin, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (Fachinformation zu Nalbuphin, Arzneimittelwechselwirkungen)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (Fachinformation zu Ofloxacin, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Rivastigmin, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (Fachinformation zu Tofacitinib, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (Fachinformation zu Tramadol, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (Fachinformation zu Tramadol und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Fachinformation zu Upadacitinib, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking sumatriptan and naproxen sodium tablets with drugs that interfere with hemostasis. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Zoledronsäure, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (Fachinformation zu Infliximab, Arzneimittelwechselwirkungen)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fachinformation zu Phentermin, Warnhinweise und Vorsichtsmaßnahmen)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (Fachinformation zu Risedronsäure, Arzneimittelwechselwirkungen)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (Fachinformation zu Tocilizumab, Arzneimittelwechselwirkungen)

Drug-drug interaction studies in healthy subjects have been conducted with zileuton immediate-release tablets and digoxin, phenytoin, sulfasalazine, and naproxen. (Fachinformation zu Zileuton, Arzneimittelwechselwirkungen)